靶向非编码基因组：超级增强子遇见它们的克星。
Targeting the Noncoding Genome: Superenhancers Meet Their Kryptonite.
机构信息
Department of Pathology and Perlmutter Cancer Center, NYU School of Medicine, New York, New York.
出版信息
Cancer Discov. 2017 Oct;7(10):1065-1066. doi: 10.1158/2159-8290.CD-17-0860.
Abstract
In this study, McKeown and colleagues carried out a genome-wide characterization and stratification of the enhancer landscape in acute myeloid leukemia (AML). The authors' analysis led to the discovery of a novel superenhancer found in a subset of patients with AML, rendering these leukemia cells highly sensitive to SY-1425, a highly potent RARA agonist able to induce myeloid differentiation in these high-expressing RARA AML subtypes. .
摘要
在这项研究中，McKeown 及其同事对急性髓系白血病 (AML) 中的增强子景观进行了全基因组特征描述和分层。作者的分析导致发现了一种新型超级增强子，存在于 AML 患者亚群中，使这些白血病细胞对 SY-1425 高度敏感，SY-1425 是一种高效的 RARA 激动剂，能够诱导这些高表达 RARA AML 亚型的髓样分化。
相似文献
1
Targeting the Noncoding Genome: Superenhancers Meet Their Kryptonite.靶向非编码基因组：超级增强子遇见它们的克星。
Cancer Discov. 2017 Oct;7(10):1065-1066. doi: 10.1158/2159-8290.CD-17-0860.
2
Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist.超级增强子分析定义了非 APL AML 的新型表观基因组亚型，包括一种新型 RARα 依赖性靶点 SY-1425，它是一种强效和选择性的 RARα 激动剂。
Cancer Discov. 2017 Oct;7(10):1136-1153. doi: 10.1158/2159-8290.CD-17-0399. Epub 2017 Jul 20.
3
Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency.定义小儿急性髓细胞白血病的转录控制，突出 RARA 作为超级增强子调控的可药物治疗的依赖性。
Blood Adv. 2021 Dec 14;5(23):4864-4876. doi: 10.1182/bloodadvances.2020003737.
4
Novel Mitochondrial Mechanisms of Cytarabine Resistance in Primary AML Cells.新型原发性急性髓细胞白血病细胞阿糖胞苷耐药的线粒体机制。
Cancer Discov. 2017 Jul;7(7):670-672. doi: 10.1158/2159-8290.CD-17-0476.
5
BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell? Venetoclax 抑制 BCL2：靶向急性髓系白血病干细胞的阿喀琉斯之踵？
Cancer Discov. 2016 Oct;6(10):1082-1083. doi: 10.1158/2159-8290.CD-16-0921.
6
Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBPα as a common target of TRIB1 and PML/RARA.急性髓系白血病和急性早幼粒细胞白血病中的协同白血病发生揭示了C/EBPα是TRIB1和PML/RARA的共同靶点。
Haematologica. 2016 Oct;101(10):1228-1236. doi: 10.3324/haematol.2015.138503. Epub 2016 Jul 6.
7
Immunologic Targets in AML.急性髓细胞白血病的免疫治疗靶点。
Blood Cancer Discov. 2023 Nov 1;4(6):430-432. doi: 10.1158/2643-3230.BCD-23-0161.
8
Activating p53 and Inhibiting Superenhancers to Cure Leukemia.激活 p53 并抑制超级增强子以治愈白血病。
Trends Pharmacol Sci. 2018 Dec;39(12):1002-1004. doi: 10.1016/j.tips.2018.10.009.
9
Eya2, a Target Activated by Plzf, Is Critical for -Induced Leukemogenesis.Eya2是一种由Plzf激活的靶点，对诱导白血病发生至关重要。
Mol Cell Biol. 2017 Jun 15;37(13). doi: 10.1128/MCB.00585-16. Print 2017 Jul 1.
10
Multiplex fusion gene testing in pediatric acute myeloid leukemia.儿童急性髓系白血病中的多重融合基因检测
Pediatr Int. 2018 Jan;60(1):47-51. doi: 10.1111/ped.13451.
引用本文的文献
1
Enhancer DNA methylation in acute myeloid leukemia and myelodysplastic syndromes.急性髓系白血病和骨髓增生异常综合征中的增强子 DNA 甲基化。
Cell Mol Life Sci. 2018 Jun;75(11):1999-2009. doi: 10.1007/s00018-018-2783-2. Epub 2018 Feb 26.
本文引用的文献
1
Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist.超级增强子分析定义了非 APL AML 的新型表观基因组亚型，包括一种新型 RARα 依赖性靶点 SY-1425，它是一种强效和选择性的 RARα 激动剂。
Cancer Discov. 2017 Oct;7(10):1136-1153. doi: 10.1158/2159-8290.CD-17-0399. Epub 2017 Jul 20.
2
Targeting Transcription Factors in Cancer.靶向癌症中的转录因子
Trends Cancer. 2015 Sep 1;1(1):53-65. doi: 10.1016/j.trecan.2015.07.001.
3
A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.一种由NOTCH1驱动的MYC增强子促进T细胞发育、转化及急性淋巴细胞白血病。
Nat Med. 2014 Oct;20(10):1130-7. doi: 10.1038/nm.3665. Epub 2014 Sep 7.
4
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.用共价 CDK7 抑制剂靶向癌症转录调控。
Nature. 2014 Jul 31;511(7511):616-20. doi: 10.1038/nature13393. Epub 2014 Jun 22.
5
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.弥漫性大 B 细胞淋巴瘤中超增强子相关依赖性的发现和特征。
Cancer Cell. 2013 Dec 9;24(6):777-90. doi: 10.1016/j.ccr.2013.11.003.
6
Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation.SWI/SNF 在急性白血病维持和增强子介导的 Myc 调控中的作用。
Genes Dev. 2013 Dec 15;27(24):2648-62. doi: 10.1101/gad.232710.113. Epub 2013 Nov 27.
7
Super-enhancers in the control of cell identity and disease.超级增强子在细胞身份和疾病中的调控作用。
Cell. 2013 Nov 7;155(4):934-47. doi: 10.1016/j.cell.2013.09.053. Epub 2013 Oct 10.
8
The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability.泛素连接酶 FBXW7 通过调节 MYC 稳定性来调节白血病起始细胞的活性。
Cell. 2013 Jun 20;153(7):1552-66. doi: 10.1016/j.cell.2013.05.041.
9
Selective inhibition of tumor oncogenes by disruption of super-enhancers.通过破坏超级增强子选择性抑制肿瘤癌基因。
Cell. 2013 Apr 11;153(2):320-34. doi: 10.1016/j.cell.2013.03.036.
10
Master transcription factors and mediator establish super-enhancers at key cell identity genes.主转录因子和中介体在关键细胞身份基因上建立超级增强子。
Cell. 2013 Apr 11;153(2):307-19. doi: 10.1016/j.cell.2013.03.035.
Zotero 插件